based on 4 analysts
50.00%
Buy
50.00%
Hold
0.00%
Sell
Based on 4 analysts offering long term price targets for Glaxosmithkline Pharmaceuticals Ltd. An average target of ₹2908.75
Source: S&P Global Market Intelligence
Glaxosmithkline Pharmaceuticals Ltd price forecast by 4 analysts
Upside of4.21%
High
₹3250
Target
₹2908.75
Low
₹2620
Glaxosmithkline Pharmaceuticals Ltd target price ₹2908.75, a slight upside of 4.21% compared to current price of ₹2698.35. According to 4 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Glaxosmithkline Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2026:20.14%
Forecast
Actual
Including amortisation and stock based compensations
Glaxosmithkline Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2026:65.52%
Forecast
Actual
Source: S&P Global Market Intelligence
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | -4.78 % |
3 Month Return | + 8.88 % |
1 Year Return | + 77.92 % |
Market Stats | |
Previous Close | ₹2,791.30 |
Open | ₹2,791.30 |
Volume | 76.78K |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹47,286.31Cr |
P/E Ratio | 62.22 |
PEG Ratio | 6.71 |
Market Cap | ₹47,286.31 Cr |
P/B Ratio | 18.45 |
EPS | 34.83 |
Dividend Yield | 1.65 |
Sector | Pharmaceuticals |
ROE | 36.83 |
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
BUY | ₹47,286.31 Cr | 20% | 0.56 | ₹589 Cr | ₹3,453 Cr | |
BUY | ₹16,459.31 Cr | 5.22% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
BUY | ₹90,184.74 Cr | 30.78% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
HOLD | ₹1,08,668.24 Cr | 70.73% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
BUY | ₹59,038.98 Cr | 36.49% | 0.53 | NA | NA |
Organisation | Glaxosmithkline Pharmaceuticals Ltd |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Key events for Glaxosmithkline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Limited received a GST demand order of ₹1.07 crore from the Telangana Commissioner for discrepancies in GST returns from FY 2017-18 to 2021-22. The company plans to appeal the order.
GSK Pharma Secures Significant Tax Refund Order - 04 Sep, 2024
Glaxosmithkline Pharmaceuticals has received an order from the Income Tax Department for a refund of Rs 222.23 crore for the Assessment Year 2022-23, enhancing its financial position.
GlaxoSmithKline Pharma Reports Tax Refund and Strong Q1 Growth - 03 Sep, 2024
GlaxoSmithKline Pharmaceuticals received a ₹222.23 crore income tax refund for FY 2022-23. The company reported a 37.8% YoY increase in Q1 net profit to ₹182.3 crore, with revenue rising 7% to ₹814.7 crore. Key brands and the respiratory portfolio showed significant growth, contributing to a strong EBITDA margin of 28.3%. Shares rose by 1.94% to ₹2,836.20.
GSK Pharma Sees Strong Gains Post Q1 Results - 21 Aug, 2024
GlaxoSmithKline Pharmaceuticals' stock rose 5.7% to Rs 3,059, marking an 11% increase since its recent results. The stock has gained 57% since April, outperforming the BSE Healthcare index and Sensex, driven by better-than-expected Q1 performance with a 7% uptick.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
FII Holding Up
Foreign Institutions have increased holdings from 3.48% to 4.02% in Jun 2024 quarter
MF Holding Up
Mutual Funds have increased holdings from 4.51% to 4.71% in Jun 2024 quarter
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 142.7% return, outperforming this stock by 58.3%
Promoter Holding Unchanged
Promoters holdings remained unchanged at 75.00% of holdings in Jun 2024 quarter
Against Peers
In the last 1 year, Torrent Pharmaceuticals Ltd has given 78.3% return, outperforming this stock by 0.4%
Price Dip
In the last 7 days, GLAXO stock has moved down by -2.5%
Retail Holding Down
Retail Investor have decreased holdings from 13.62% to 13.48% in Jun 2024 quarter
Revenue Fall
Revenue is down for the last 2 quarters, 962.03 Cr → 850.29 Cr (in ₹), with an average decrease of 11.6% per quarter
Profit Down
Netprofit is down for the last 2 quarters, 194.48 Cr → 182.33 Cr (in ₹), with an average decrease of 6.3% per quarter
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 75% | 0.00 | |
Foreign Institutions | 4.02% | 15.51 | |
Mutual Funds | 4.71% | 4.38 | |
Retail Investors | 13.48% | ||
Others | 2.8% |
Glaxosmithkline Pharmaceuticals Ltd in the last 5 years
Lowest (-81.64x)
December 28, 2020
Industry (58.50x)
September 18, 2024
Today (62.22x)
September 18, 2024
Highest (333.07x)
September 15, 2020
Glaxosmithkline Pharmaceuticals Ltd’s net profit jumped 37.87% since last year same period to ₹182.33Cr in the Q1 2024-2025. On a quarterly growth basis, Glaxosmithkline Pharmaceuticals Ltd has generated -6.25% fall in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending March 2024, Glaxosmithkline Pharmaceuticals Ltd has declared dividend of ₹32 - translating a dividend yield of 2.29%.
Read More about DividendsBearish
Neutral
Bullish
Glaxosmithkline Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.
Glaxosmithkline Pharmaceuticals Ltd (GLAXO) share price today is ₹2698.35
Glaxosmithkline Pharmaceuticals Ltd is listed on NSE
Glaxosmithkline Pharmaceuticals Ltd is listed on BSE
PE Ratio of Glaxosmithkline Pharmaceuticals Ltd is 62.22
PE ratio = Glaxosmithkline Pharmaceuticals Ltd Market price per share / Glaxosmithkline Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Glaxosmithkline Pharmaceuticals Ltd(GLAXO) is 76.78K.
Today’s market capitalisation of Glaxosmithkline Pharmaceuticals Ltd(GLAXO) is ₹47286.31Cr.
Glaxosmithkline Pharmaceuticals Ltd(GLAXO | Price |
---|---|
52 Week High | ₹3088 |
52 Week Low | ₹1385.05 |
Glaxosmithkline Pharmaceuticals Ltd(GLAXO) share price is ₹2698.35. It is down -12.62% from its 52 Week High price of ₹3088
Glaxosmithkline Pharmaceuticals Ltd(GLAXO) share price is ₹2698.35. It is up 94.82% from its 52 Week Low price of ₹1385.05
Glaxosmithkline Pharmaceuticals Ltd(GLAXO | Returns |
---|---|
1 Day Returns | -92.95% |
1 Month Returns | -4.78% |
3 Month Returns | 8.88% |
1 Year Returns | 77.92% |